Vascular Therapies focuses on improving vascular access for hemodialysis patients, particularly addressing the challenges associated with arteriovenous (AV) grafts and fistulas. The company highlights the significant issues of stenosis, which affects up to 50% of AV fistulas and grafts within 6-12 months post-surgery. To combat this, Vascular Therapies has developed Sirogen™, a bioabsorbable implant that delivers sirolimus, a drug known for its ability to prevent blood vessel narrowing. This innovative approach aims to maintain blood flow and ensure the longevity of vascular access, ultimately reducing the reliance on central venous catheters, which are associated with higher risks of complications such as infections and thrombosis.

Sirogen™ is designed to be applied during the surgical creation of the fistula, specifically targeting areas prone to stenosis. The ongoing ACCESS 2 clinical study is evaluating the effectiveness of Sirogen™ in increasing the usability of fistulas for hemodialysis, shortening the time required for a fistula to mature, and decreasing the number of fistulas that are abandoned. By achieving these goals, Vascular Therapies aims to enhance patient outcomes, reduce the need for catheters, and improve the overall efficiency of dialysis treatment.

United States

Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery.

Sirogen™ is currently undergoing clinical trials to determine its safety and effectiveness in improving vascular access outcomes in patients requiring an arteriovenous fistula for hemodialysis.

Vascular Therapies

Company Details